Navigation Links
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Date:5/28/2009

nt plans, the potential safety and efficacy of its products in development and commercialization strategy. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Report on Form 10-Q for the period ended March 31, 2009, which was filed with the SEC on May 11, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

(1) American Cancer Society, Cancer Facts and Figures 2008


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
2. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
3. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
4. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
5. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
6. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
7. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
8. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
9. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
10. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...swire-USNewswire/ -- Remedium Technologies Inc., a... stops severe bleeding, won first prize and $10,00...the Global Security Challenge 2009, company offici...100 entries from around the world, Remedium,s team...t conference held at the London School of Business...
(Date:11/25/2009)...wswire/ -- Regado Biosciences, a privately held co...tamers with active control agents, announced that ...nting at the Piper Jaffray 21st Annual Health Care...rk City. Dr. Mazzo,s presentation will be given a...lude an overview of the Company,s pipeline with em...
(Date:11/25/2009).../ -- Reportlinker.com announces that a new market ..., United States Dental Devices Market Analysis a...er.com/p0158733/United-States-Dental-Devices-Marke...d States Dental Devices Market Analysis and Foreca...n essential source for in-depth information and da...
Breaking Medicine Technology:Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 13Making more efficient fuel cells 9811 1Largest ever Alzheimers genome study unveils dementia mysteries 9809 1Largest ever Alzheimers genome study unveils dementia mysteries 9809 2Largest ever Alzheimers genome study unveils dementia mysteries 9809 3Veterans to TEE Off in Iowa City at National Tournament 56329 1Veterans to TEE Off in Iowa City at National Tournament 56329 2
...KVILLE, Md., May 5th Scientists from University o...land and OriGene,Technologies joined effort in cre...nearly all predicted human protein kinases, includ...ent counterparts. Equipped with,this collection, t...gulators in Hedgehog signaling pathway and in acti...
...trogen Continues to be Gold Standard for Managemen...ical specialists from,around the country will gath...tetrics and gynecology, and menopause and estrogen... "Estrogen therapy continues to be the gold stand...mmon physical sign of menopause," said Dr. Ricki,P...
Other Medicine Technology:Latest Cell Publication Describes the Novel Kinase Regulators Using OriGene's Functional Kinome Collection 2Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause 2Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause 3
(Date:11/27/2009)... Biotech firm Replikins Ltd. tod...1N1 virus genomic data. It shows that the lethali...s.d. 4.5) during the virus,s current outbreak in t...his week of 2.0 (s.d. 0.1). The H1N1 infectivity c... Boston (PRWEB) November 27, 2009 -- Bio...
(Date:11/27/2009)... , NEUILLY-SUR-SEINE, France, Nov. 27 /PRNewsw... professional cycling team dedicated to ethical sp...ng champions, announced today that it will become ...itions Optical as a new sponsor of the team. Trans... of adaptive eyewear, offering the most advanced p...
(Date:11/27/2009)... rates to bring unprecedented medical, economic bu...7 (HealthDay News) -- The number of people with di...over the next 25 years, a new study predicts. ,...million people with the disease, up from 23.7 mill...ating people with diabetes will triple, the study ...
(Date:11/27/2009)... Specialist manufacturers who us...s are saving millions of dollars by bringing in te...ss. Increasing numbers of pro-active medical manuf...at the concept stage of their projects, ensuring t...esign processes or potentially outdated technology...
(Date:11/26/2009)...e next 25 years, the number of Americans living wi....7 million in 2009 to 44.1 million in 2034. Over t...riple, rising from $113 billion to $336 billion, e... researchers based at the University of Chicago re... The number of those with diabetes covered by Medi...
Breaking Medicine News(10 mins):Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3
...1998 to 301 in 2006, the maternal mortality ratio ...dbirth //has been falling in India, albeit gradual...od Day Wednesday, it hopes to reduce the MMR rate,... that works to ensure safe motherhood, credits the...
...with Parkinson's disease are less likely to smoke ...y members who do not have the disease//, according...caffeine and taking non-steroidal anti-inflammator...ng to background information in the article. Howev...
...ished in the April 10, 2007, issue of Neurology, h... disease in patients// suffering ‘Restless Legs Sy...tients. For the study, conducted at the Univ...eg movements and blood pressure changes. RLS is a ...
...eport has come out with news that would gladden th...nies, as well as strike fear// in the minds of th...r Peter Singer of the McLaughlin-Rotman Center for...ers about 21 Indian biotechnology companies. ...
... data released by Banfield, The Pet Hospital, one ...he US, nearly 39,000 cats and dogs// were sickened...mination with an industrial chemical. The d...pet food. Described as one of the largest in U.S. ...
...cident can change a person's entire life from one ...njury often takes less time// to heal than the psy...ts differently to shock," says Erneli Martens, a p...reaming is seldom the case, she says. "Some people...
Other Medicine News:Health News:Ray of Hope for Women on Motherhood Day 2Health News:Smoking and Caffeine Inversely Associated With Parkinson's Disease 2Health News:Restless Legs Syndrome Poses Risk of Cardiovascular Disease 2Health News:India’s Biotech Companies- Jumbos Waiting to Gro 2Health News:Melamine Contamination Killed Thousands of Pets, Says a New Report 2Health News:Accident Victims Often Need Psychological Help 2
...le ergonomic chairs with concave seats and large b... like seats, backrests, armrests, and casters and ...mance in a variety of environments including: indu...ntrol, health care and office. • With cast al...
...le ergonomic chairs with concave seats and large b... like seats, backrests, armrests, and casters and ...mance in a variety of environments including: indu...ntrol, health care and office. • With cast al...
BEC/1Q-ERB - Cast Aluminum Base - Model 1Q72-ERB
BET/1P-ERB - Tubular Base - Model 1P63
Medicine Products: